BIO analyst estimates
Bio-Rad (BIO) analyst ratings, the average price target and its range, and every firm's latest call.
BIO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Bio-Rad price target raised to $390 from $370 at RBC Capital | $390.00 |
| Aug 5, 2026 | RBC Capital | Bio-Rad price target raised to $370 from $320 at RBC Capital | $370.00 |
| May 25, 2026 | Wells Fargo | Bio-Rad price target raised to $310 from $290 at Wells Fargo | $310.00 |
| May 14, 2026 | RBC Capital | Bio-Rad resumed with an Outperform at RBC Capital | $320.00 |
| May 1, 2026 | Wells Fargo | Bio-Rad price target lowered to $290 from $320 at Wells Fargo | $290.00 |
| Feb 16, 2026 | Wells Fargo | Bio-Rad price target lowered to $320 from $340 at Wells Fargo | $320.00 |
| Feb 13, 2026 | UBS | Bio-Rad price target lowered to $335 from $350 at UBS | $335.00 |
| Oct 30, 2025 | Wells Fargo | Bio-Rad price target raised to $340 from $265 at Wells Fargo | $340.00 |
| Oct 1, 2024 | Citigroup | Citi Upgrades Bio-Rad Labs (BIO) to Buy | $400.00 |
| Dec 7, 2022 | RBC Capital | RBC Capital Initiates Coverage On Bio-Rad Laboratories with Outperform Rating, Announces Price Target of $565 | $565.00 |
- 3 firms rate BIO: 1 buy, 2 hold, 0 sell.
- The average price target is $350.00 from 2 analysts, from $310.00 to $390.00.
Updated 2026-11-02 23:12 UTC